The Conjunctivitis PPP was sent for review in July 2023 to improve the quality of the guideline, to gather feedback on the draft recommendations and to assess feasibility for and applicability to the target audience,including assessing the facilitators and barriers to implementing recommendations (e.g., U.S.ophthalmologists and other important groups, including patients, other physicians, international ophthalmologists, research organizations, ophthalmological organizations, and experts in the field). The PPP was sent for review to the following patient organizations to solicit the views and preferences of patients and the public: Consumers United for Evidence-Based Healthcare, American Foundation for the Blind,Foundation Fighting Blindness, Lighthouse Guild, National Federation of the Blind, and Prevent Blindness.All those returning comments were required to provide disclosure of relevant relationships with industry to have their comments considered (indicated with an asterisk below). Members of the Cornea/External Disease Preferred Practice Pattern Panel reviewed these comments and determined revisions to the document.